Übersicht · Eingereicht: —
ACT_547520/2023
VerletzungHauptverletzungsklageMunich LDInfringement Action—
Parteien
Kläger
- Dexcom Inc.(Dexcom Group)
Vertreter: (Quinn Emanuel Urquhart & Sullivan, LLP)
Beklagte
- Abbott Laboratories(Abbott Group)
- Abbott Diabetes Care Inc.(Abbott Group)
- Abbott GmbH(Abbott Group)
- Abbott Diagnostics GmbH(Abbott Group)
- Abbott Logistics B.V.(Abbott Group)
- Abbott (S.A./N.V.)(Abbott Group)
- Abbott s.r.l.(Abbott Group)
- Abbott B.V.(Abbott Group)
- Abbott Scandinavia Aktiebolag(Abbott Group)
Vertreter:
Richter
- Matthias ZigannPresiding judge
- Tobias PichlmaierJudge-rapporteur
- Tatyana ZhilovaLegally qualified judge
- Alain DumontTechnically qualified judge
Patente
- EP 3 350 592
Technologiebereich: Medical Devices · CGM
Ausgang
Nichtig erklärtAbgewiesen — Patent ungültig
Eingereicht: —
Erste Entscheidung: 31. Juli 2024
Sprache: —
Munich Local Division revoked DexCom's patent EP 3 350 592 (CGM system) in its entirety on Abbott's counterclaim for revocation, and dismissed all of DexCom's infringement claims. The patent was found invalid as granted and in its auxiliary request forms (1 and 2) for lack of novelty/inventive step. DexCom was ordered to bear all costs of the proceedings.
Ansprüche
Streitigall
Nichtig erklärtall
Hinweise: EP 3 350 592 revoked in its entirety; independent claim 1 and all dependent claims found invalid; infringement action dismissed.